Dr Benjamin Lowentritt is a board-certified urologist at Chesapeake Urology and has been seeing patients for the treatment of advanced prostate cancer for over 15 years.
He was named Director of Prostate Cancer Services for United Urology in 2018 after serving as the Director of Prostate Cancer Care Program and Director, Minimally invasive Surgery and Robotics at Chesapeake Urology, a member of United Urology’s group practices. Dr Lowentritt is a member of United Urology’s Executive Clinical Team. As Director, Dr Lowentritt is responsible for working with member practices to build and optimize services for prostate cancer patients. He has been at the forefront of robotic urology procedures and was the first surgeon in Maryland to perform robot-assisted surgery for bladder cancer.
“Hi, I’m Dr Benjamin Lowentritt. I’m a urologist at Chesapeake Urology, and I’ve been seeing patients for the treatment of advanced prostate cancer for 15 years. In my practice, each patient’s treatment plan is individualized to that specific patient, and when prescribing a GnRHa, my thoughts go to LUPRON DEPOT.
Early in my career, LUPRON DEPOT was ADT—the two were synonymous to me. In my mind, the fact that LUPRON DEPOT remains a market leader after more than 30 years speaks to a reassuring commitment to treating patients with advanced prostate cancer.
Drawing on my experience, and what I’ve observed from my colleagues, LUPRON DEPOT is still the ADT many of us reach for when treating patients with advanced prostate cancer. In my experience, it checks the boxes: an established efficacy and safety profile, flexible dosing options, and an innovative delivery system.
Each of the clinical studies for the 1, 3, 4, and 6-month doses has demonstrated efficacy in suppressing testosterone, so I know what to expect, and I can tailor the dosing schedule to one that fits my patient’s needs. I remember when the 4-month dose came to market in 1997, allowing patients to spread out their treatments over the course of a year. And, since 2011, the 6-month dose has added to that flexibility as well.
Treating each patient as an individual is so fundamental to the way we practice medicine in general and the way we manage patients with advanced prostate cancer. Having the flexibility of different dosing schedules is one way to individualize care depending on how stable a patient is with their therapy and how frequently I need to monitor their testosterone levels, PSA levels, and any side effects.
It’s important to note that LUPRON DEPOT is contraindicated in individuals with known hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT.
Whenever I test a patient’s PSA level, I also test and monitor their testosterone level. While this isn’t standard practice, testing both testosterone and PSA levels gives me a more complete picture of what’s going on with my patients.
In my experience, it’s as simple as adding the testosterone test to the same blood draw for the PSA test. Routinely monitoring testosterone helps me treat my patients more proactively because I can see any changes in testosterone levels before these changes may affect PSA levels. And I can monitor these results every time my patients visit the office for their ADT injections.
When it comes to administering LUPRON DEPOT, the first thing that comes to mind is how much our staff appreciates the innovative delivery system. It doesn’t have to be refrigerated, so it doesn’t take time to warm up before use. It comes in a complete injection kit that has a prefilled dual-chamber syringe, which requires no external mixing. And my staff definitely values the LuproLoc® safety system that helps prevent accidental needlesticks.
In our experience, patients also appreciate that LUPRON DEPOT uses a fine, 23-gauge, intramuscular needle And because it comes in a complete injection kit that has everything needed to administer, our staff finds the process quick and efficient.
Part of my approach is treating the patient as a whole, and part of that is helping them become informed. When I diagnose a patient with advanced prostate cancer, or when a patient comes to me after a recent diagnosis, they’re usually in a vulnerable place—worried, confused, and anxious about what comes next. The educational materials that AbbVie provides to my practice deliver key information for LUPRON DEPOT patients about their condition that they can refer to after they leave my office—at their own pace, on their own time.
Supporting patients with information they need at a critical time in their lives is an important part of empowering them to actively participate in their treatment.”